The Tryst Network provided a sex-positive pool of resources to improve the sexual health IQ of women and their partners through fun, reliable and empowering online content.
LACTIN-V
LACTIN-V
LACTIN-V is being registered in South Africa for use in the FRESH clinical study. FRESH follows young women at risk for HIV and, among other objectives, regularly checks the parameters of their vaginal microbiome. Many women in the study have microbiota depleted of normal Lactobacillus strains, which leaves them vulnerable to infections, including HIV. One arm of the study hopes to show that LACTIN-V could decrease genital tract inflammation and lower their HIV acquisition risk.
Catalyst Global’s regulatory support includes regulatory planning, facilitation of the pre-registration (Type C) meeting with the South African regulatory authority, preparation and submission of the clinical trial application to the regulatory authority and the ethics committees, and subsequent protocol amendment submission and ongoing support.
Our team communicates with the regulatory authority and the ethics committees throughout the study to facilitate the finalization of the regulatory processes needed prior to clinical trial initiation. We also provide assistance for the submission and renewal of clinical trial insurance, including reviewing drafts of study documents such as the protocol and informed consent to ensure compliance with requirements and communicating with the sponsor, UCSF.
Countries:
South Africa
Project duration:
2017 – 2022
Funder:
University of California, San Francisco (UCSF)
Product:
Biotherapeutic product aimed at reducing HIV transmission (LACTIN-V)
“As an academic researcher from the US with limited expertise in navigating global drug regulatory pathways, the excellent guidance by WCG’s team (now Catalyst Global) was foundational for the planning and implementation of our clinical study in South Africa. It is critical to have local regulatory experts on your team, even more so when a global pandemic is slowing everything down.”
Anke Hemmerling, MD PhD MPH, Professor,
Department of Obstetrics, Gynecology & Reproductive Sciences; UCSF
Related posts
Maximizing Health Care Provider Performance (MAX)
The MAX intervention worked with health care providers to address individual and structural barriers constraining sexual and reproductive health services and contraception provision in Kenya and South Africa.
Dual Prevention Pill (DPP) Acceptability Study
With funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the Expanding Effective Contraceptive Options (EECO) project, Catalyst Global collaborates with Population Council and the Wits Reproductive Health and HIV Institute on the implementation of an acceptability study of the Dual Prevention Pill (DPP), a multipurpose prevention technology that combines oral pre-exposure prophylaxis (PrEP) and an oral contraceptive, in South Africa.